AGIO News Alert Agios Pharmaceuticals Inc (AGIO) 119.56 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Agios Pharmaceuticals Inc (AGIO) 119.56 $AGIO

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 12, 7:38PM CST
Cramer will be watching company earnings while keeping an eye on oil futures to get a sense of where the market will move.
MMM: 157.12 (-2.03), SWX: 57.19 (-1.09), HON: 95.88 (-2.01), NKE: 96.17 (-0.76), CHTR: 162.95 (-1.21), BBRY: 9.84 (-0.32), XON: 27.01 (+0.35), RMTI: 8.20 (+0.04), KMX: 58.30 (-1.21), MEMP: 13.13 (-0.96), ACAD: 32.53 (-0.10), PAYX: 46.10 (-0.77), AGU: 91.53 (-2.47), TRUE: 21.35 (-1.68), LOW: 64.87 (-0.89), TWTR: 37.10 (+0.40), REGN: 416.44 (-7.91), JOY: 46.28 (-2.80), FDX: 175.79 (-1.09), LBRDA: 49.07 (-1.58), FINL: 28.32 (+0.15), ORCL: 39.95 (-0.81), DRI: 57.38 (-0.45), BAX: 71.77 (-1.34), RHT: 57.87 (-0.55), AGIO: 119.56 (+0.36), PAY: 33.01 (-1.47), PG: 89.55 (-0.86)

Agios Pharmaceuticals (AGIO) Looks Good: Stock Up 6.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:25AM CST
Agios Pharmaceuticals (AGIO) was a big mover last session, with shares rising nearly 7% on the day.
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), AGIO: 119.56 (+0.36), OSUR: 9.49 (-0.25)

The Nominees for Best Biotechnology Co. CEO of 2014 Are...
at The Street - Fri Dec 12, 5:05AM CST
The CEOs of Exact Sciences, Idenix Pharma, Prosensa, Agios, Bluebird Bio and InterMune vie for the coveted title of Best Biotech CEO
BLUE: 91.28 (+5.16), RNA: 18.76 (-0.21), EXAS: 27.96 (-0.24), AGIO: 119.56 (+0.36)

Agios prices offering
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:19AM CST

AGIO: 119.56 (+0.36)

Agios Pharmaceuticals expects USD220m from public offering
M2 - Thu Dec 11, 5:56AM CST
Biopharmaceutical company Agios Pharmaceuticals (NasdaqGS:AGIO) said on Wednesday that it has priced its public offering of 1,986,455 shares of its common stock.
AGIO: 119.56 (+0.36)

Jim Cramer's Top Stock Picks: RH COST AGIO BLUE ISIS
at The Street - Thu Dec 11, 5:00AM CST
Restoration Hardware and Costco should benefit from lower oil prices, and the recent drop in Agios' and Bluebird Bio's shares means a buying opportunity, Cramer says.
BLUE: 91.28 (+5.16), RH: 93.59 (-0.40), ISIS: 62.32 (+0.45), COST: 137.88 (-3.53), AGIO: 119.56 (+0.36)

Cramer's Mad Money - The Good Isis (12/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Thu Dec 11, 3:43AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday December 10. CEO Interview: Dr. Stanley Crooke, Isis Pharmaceuticals (NASDAQ: ISIS ) Isis Pharmaceuticals ( ISIS ) produces treatments that bind to...
BLUE: 91.28 (+5.16), TSLA: 207.00 (-1.88), RH: 93.59 (-0.40), FRPT: 17.14 (-0.88), BA: 120.77 (-2.60), CELG: 114.49 (-2.25), XLV: 68.78 (-1.07), RFMD: 15.50 (-0.29), NOV: 61.55 (-1.46), ISIS: 62.32 (+0.45), KITE: 54.79 (+0.39), TQNT: 25.87 (-0.51), COST: 137.88 (-3.53), AGIO: 119.56 (+0.36), VZ: 45.58 (-0.78), CSCO: 26.85 (-0.14)

Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock
GlobeNewswire - Wed Dec 10, 7:41PM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 1,986,455 shares of common stock at a price to the public of $110.75 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $220 million. All of the shares in the offering are to be sold by Agios. Agios has also granted the underwriters a 30-day option to purchase up to an additional 297,968 shares of common stock on the same terms and conditions. Closing of the offering is expected to occur on or about December 16, 2014, subject to customary closing conditions.
JPM: 60.04 (-1.10), AGIO: 119.56 (+0.36)

Jim Cramer's 'Mad Money' Recap: The Good News-Bad News of Lower Oil Prices
at The Street - Wed Dec 10, 7:41PM CST
The negative effects of oil below $60 per barrel on certain companies could outweigh the gains seen from higher consumer spending, at least in the short term, Cramer says.
TSLA: 207.00 (-1.88), RH: 93.59 (-0.40), F: 14.99 (-0.29), EMES: 44.67 (+0.92), BOKF: 58.67 (-1.75), FRPT: 17.14 (-0.88), BPT: 67.95 (-2.57), HBHC: 29.40 (-0.82), PBR: 7.11 (-0.31), T: 32.16 (-0.55), CFR: 70.00 (-1.62), SAVE: 68.12 (-0.88), JPM: 60.04 (-1.10), COST: 137.88 (-3.53), XLF: 24.14 (-0.48), BLUE: 91.28 (+5.16), BA: 120.77 (-2.60), CELG: 114.49 (-2.25), ISIS: 62.32 (+0.45), KITE: 54.79 (+0.39), CONN: 17.44 (+0.35), JCP: 6.38 (+0.29), GM: 31.57 (-0.62), AGIO: 119.56 (+0.36), PAY: 33.01 (-1.47)

Agios Pharmaceuticals to issue up to USD175m common stock in public offering
M2 - Wed Dec 10, 6:26AM CST
Biopharmaceutical company Agios Pharmaceuticals (NasdaqGS:AGIO) said on Tuesday that it plans to launch up to USD175m of its common stock in a public offering.
AGIO: 119.56 (+0.36)

Agios Pharmaceuticals hires Kaye Foster-Cheek to board
M2 - Wed Dec 10, 6:11AM CST
Cancer company Agios Pharmaceuticals (NasdaqGS:AGIO) revealed on Tuesday the addition of Kaye Foster-Cheek as an independent director of its board of directors.
AGIO: 119.56 (+0.36)

Agios Pharmaceuticals Announces Proposed Offering of Common Stock
GlobeNewswire - Tue Dec 09, 3:22PM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $175 million of its common stock in an underwritten public offering. Agios also intends to grant the underwriters a 30-day option to purchase from it up to an additional $26.3 million of shares. All of the shares in the offering are to be sold by Agios. The proceeds of the offering are expected to be used to fund the company's clinical and research development activities. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
JPM: 60.04 (-1.10), AGIO: 119.56 (+0.36)

Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors
GlobeNewswire - Tue Dec 09, 3:01PM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the addition of Kaye Foster-Cheek as an independent director to the company's board of directors, effective immediately. Ms. Foster-Cheek is the former senior vice president, global human resources at Onyx Pharmaceuticals, Inc. an Amgen subsidiary. Agios' board also appointed Ms. Foster-Cheek as a member of its compensation committee and elected her to the class of directors whose term expires in 2015. The company's board now has a total of 10 members.
AGIO: 119.56 (+0.36)

Agios (AGIO) Reports Encouraging Data on Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 3:35PM CST
Agios Pharmaceuticals, Inc. (AGIO) announced new data from the ongoing phase I dose escalation study on pipeline candidate AG-221.
AGN: 208.47 (-2.67), BIIB: 344.49 (+2.16), AGIO: 119.56 (+0.36), CELG: 114.49 (-2.25)

Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency
GlobeNewswire - Mon Dec 08, 12:00PM CST
AG-348 Achieved Proof-of-Mechanism Through Substantial Effects on Two Key Biomarkers of Pyruvate Kinase Activity and Pathway Activation
AGIO: 119.56 (+0.36)

Agios Announces Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to April 2016
GlobeNewswire - Mon Dec 08, 6:30AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that Celgene Corporation has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The extension marks the final year for the discovery phase as outlined under the terms of the collaboration, which gives Celgene an exclusive option to drug candidates generated by Agios' cancer metabolism platform during this time. The terms of the collaboration extension are consistent with previously agreed upon financial terms.
AGIO: 119.56 (+0.36), CELGZ: 3.51 (-0.03)

The 7 Most Important Drug-Stock Lessons From This Weekend's Blood Cancer Meeting
at The Street - Mon Dec 08, 6:15AM CST
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
BLUE: 91.28 (+5.16), SGEN: 32.25 (-1.49), MRK: 57.72 (-1.62), SNSS: 2.26 (unch), AGIO: 119.56 (+0.36), BMY: 58.75 (-0.93), XLRN: 41.77 (+0.29), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)

Cramer's Mad Money - Ulta Salon Is Looking Good (12/5/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Mon Dec 08, 4:43AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday December 5. Ulta Salon (NASDAQ: ULTA ) Is Looking Good Ulta Salon ( ULTA ) was up on Friday, and Cramer recalled a time when it seemed management was...
RH: 93.59 (-0.40), UTX: 112.15 (-1.89), CAH: 79.30 (-1.17), AMGN: 164.53 (-1.55), DIS: 91.49 (-0.26), AZO: 604.73 (+2.34), GILD: 104.13 (-0.18), SHPG: 213.70 (-0.41), COST: 137.88 (-3.53), ABBV: 65.27 (-1.76), AGIO: 119.56 (+0.36), DOV: 67.82 (-2.33), ULTA: 128.67 (-0.77), IDXX: 148.86 (-0.23), LE: 47.60 (+0.77), MBLY: 40.78 (-1.19)

3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user  Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 344.49 (+2.16), ISIS: 62.32 (+0.45), OMED: 19.77 (-0.42), GILD: 104.13 (-0.18), TEVA: 55.92 (-0.92), EPZM: 18.35 (-1.45), AGIO: 119.56 (+0.36), SNY: 45.16 (-1.05), FOLD: 8.15 (+0.18), XLRN: 41.77 (+0.29), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)

Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
GlobeNewswire - Sun Dec 07, 11:30AM CST
Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers
AGIO: 119.56 (+0.36)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 50

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 168

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 202

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 136

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 29

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 153

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 11

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading

Top 5 Most Recently Viewed Articles

Ohmyhome Prepares to Share Exciting Q3 2024 Growth Insights

Updated Category News Views 84

Ohmyhome Set to Unveil Q3 2024 Growth Insights As a leading property technology platform, Ohmyhome Ltd. (NASDAQ: OMH) has established itself as a prominent player in the real estate market. The company specializes in offering comprehensive solutions ranging from brokerage, renovation, and management services for properties in the region. As consumers increasingly look for...

Continue Reading
Innovative Partnership Between TotalEnergies and Emerson Energizes Industrial Data Solutions

Updated Category News Views 344

Transforming Industrial Data Management TotalEnergies and Emerson are uniting to implement extensive industrial data collection solutions across TotalEnergies' operational landscape. This exciting partnership aims to harness continuous and real-time data collection to significantly enhance operational efficiency, energy utilization, and environmental performance at...

Continue Reading
Doré Copper and Cygnus Metals Forge New Mineral Giant Together

Updated Category News Views 114

Doré Copper and Cygnus Metals Join Forces for a Stronger Future Doré Copper Mining Corp. (TSXV: DCMC; OTCQB: DRCMF; FRA: DCM) is thrilled to announce an exciting development. The company has entered into a definitive arrangement agreement with Cygnus Metals Limited (ASX: CY5) to merge their businesses. This is not just any merger; it's a merger of equals that aims to...

Continue Reading
G Mining Ventures Unveils Key Corporate Developments

Updated Category News Views 132

G Mining Ventures Unveils Key Corporate Developments G Mining Ventures Corp. has been making headlines as it continues to expand its influence in the mining industry. The company is dedicated to innovating its strategies while navigating the complexities of market dynamics. By focusing on sustainable practices and operational efficiency, G Mining Ventures aims to enhance...

Continue Reading
Neutrinos Launches Innovative Suite to Transform Insurance Underwriting

Updated Category News Views 489

Neutrinos Launches Innovative Suite for Underwriting Automation In a transformative leap forward for the insurance industry, Neutrinos has introduced its Underwriting Automation Suite, tailored specifically for life, annuities, and health insurance. This cutting-edge tool aims to streamline underwriting workflows, enhance risk assessments, and ultimately elevate...

Continue Reading